Adaptability of the semi-invariant natural killer T-cell receptor towards structurally diverse CD1d-restricted ligands
- PMID: 19816402
- PMCID: PMC2782097
- DOI: 10.1038/emboj.2009.286
Adaptability of the semi-invariant natural killer T-cell receptor towards structurally diverse CD1d-restricted ligands
Erratum in
-
Adaptability of the semi-invariant natural killer T-cell receptor towards structurally diverse CD1d-restricted ligands.EMBO J. 2009 Dec 2;28(23):3781. doi: 10.1038/emboj.2009.348. EMBO J. 2009. PMID: 19953109 Free PMC article.
Abstract
The semi-invariant natural killer (NK) T-cell receptor (NKTcr) recognises structurally diverse glycolipid antigens presented by the monomorphic CD1d molecule. While the alpha-chain of the NKTcr is invariant, the beta-chain is more diverse, but how this diversity enables the NKTcr to recognise diverse antigens, such as an alpha-linked monosaccharide (alpha-galactosylceramide and alpha-galactosyldiacylglycerol) and the beta-linked trisaccharide (isoglobotriaosylceramide), is unclear. We demonstrate here that NKTcrs, which varied in their beta-chain usage, recognised diverse glycolipid antigens with a similar binding mode on CD1d. Nevertheless, the NKTcrs recognised distinct epitopic sites within these antigens, including alpha-galactosylceramide, the structurally similar alpha-galactosyldiacylglycerol and the very distinct isoglobotriaosylceramide. We also show that the relative roles of the CDR loops within the NKTcr beta-chain varied as a function of the antigen. Thus, while NKTcrs characteristically use a conserved docking mode, the NKTcr beta-chain allows these cells to recognise unique aspects of structurally diverse CD1d-restricted ligands.
Conflict of interest statement
SA Porcelli serves as a paid consultant for Vaccinex Inc., Rochester, NY. The remaining authors have no conflicting financial interests.
Figures
References
-
- Borg NA, Wun KS, Kjer-Nielsen L, Wilce MC, Pellicci DG, Koh R, Besra GS, Bharadwaj M, Godfrey DI, McCluskey J, Rossjohn J (2007) CD1d–lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature 448: 44–49 - PubMed
-
- Burdin N, Brossay L, Koezuka Y, Smiley ST, Grusby MJ, Gui M, Taniguchi M, Hayakawa K, Kronenberg M (1998) Selective ability of mouse CD1 to present glycolipids: alpha-galactosylceramide specifically stimulates Valpha14+ NK T lymphocytes. J Immunol 161: 3271–3281 - PubMed
-
- Cantu C III, Benlagha K, Savage PB, Bendelac A, Teyton L (2003) The paradox of immune molecular recognition of alpha-galactosylceramide: low affinity, low specificity for CD1d, high affinity for alpha beta TCRs. J Immunol 170: 4673–4682 - PubMed
-
- Capone M, Cantarella D, Schumann J, Naidenko OV, Garavaglia C, Beermann F, Kronenberg M, Dellabona P, MacDonald HR, Casorati G (2003) Human invariant Valpha24–JalphaQ TCR supports the development of CD1d-dependent NK1.1+ and NK1.1− T cells in transgenic mice. J Immunol 170: 2390–2398 - PubMed
-
- Chen W, Xia C, Wang J, Thapa P, Li Y, Nadas J, Zhang W, Zhou D, Wang PG (2007) Synthesis and structure–activity relationship study of isoglobotrihexosylceramide analogues. J Org Chem 72: 9914–9923 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 AI057519/AI/NIAID NIH HHS/United States
- R01 AI061721/AI/NIAID NIH HHS/United States
- AI061721/AI/NIAID NIH HHS/United States
- AI074952/AI/NIAID NIH HHS/United States
- R01 AI045889/AI/NIAID NIH HHS/United States
- AI45889/AI/NIAID NIH HHS/United States
- R01 AI074952/AI/NIAID NIH HHS/United States
- U01 AI048224/AI/NIAID NIH HHS/United States
- AI048224/AI/NIAID NIH HHS/United States
- R01 AI042284/AI/NIAID NIH HHS/United States
- HL069765/HL/NHLBI NIH HHS/United States
- AI057519/AI/NIAID NIH HHS/United States
- AI007611/AI/NIAID NIH HHS/United States
- T32 HL069765/HL/NHLBI NIH HHS/United States
- R56 AI078246/AI/NIAID NIH HHS/United States
- R01 HL121139/HL/NHLBI NIH HHS/United States
- T32 AI007611/AI/NIAID NIH HHS/United States
- R56 AI074952/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
